Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cemiplimab: First Global Approval.

Literature DB >> 30456447

Cemiplimab: First Global Approval.

Abstract

Cemiplimab (LIBTAYO®; cemiplimab-rwlc), a human programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2), is being developed by Regeneron Pharmaceuticals and Sanofi Genzyme. The drug is being investigated as a treatment for various cancers and in September 2018 received approval in the USA for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. This article summarizes the milestones in the development of cemiplimab leading to this first global approval for the treatment of advanced cutaneous squamous cell carcinoma.

Entities: Chemical

Mesh：

Substances：

Year: 2018 PMID： 30456447 DOI： 10.1007/s40265-018-1012-5

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 11.431

2 in total

1. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.

Authors: Elena Burova; Aynur Hermann; Janelle Waite; Terra Potocky; Venus Lai; Seongwon Hong; Matt Liu; Omaira Allbritton; Amy Woodruff; Qi Wu; Amanda D'Orvilliers; Elena Garnova; Ashique Rafique; William Poueymirou; Joel Martin; Tammy Huang; Dimitris Skokos; Joel Kantrowitz; Jon Popke; Markus Mohrs; Douglas MacDonald; Ella Ioffe; William Olson; Israel Lowy; Andrew Murphy; Gavin Thurston
Journal: Mol Cancer Ther Date: 2017-03-06 Impact factor: 6.261

2. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Authors: Michael R Migden; Danny Rischin; Chrysalyne D Schmults; Alexander Guminski; Axel Hauschild; Karl D Lewis; Christine H Chung; Leonel Hernandez-Aya; Annette M Lim; Anne Lynn S Chang; Guilherme Rabinowits; Alesha A Thai; Lara A Dunn; Brett G M Hughes; Nikhil I Khushalani; Badri Modi; Dirk Schadendorf; Bo Gao; Frank Seebach; Siyu Li; Jingjin Li; Melissa Mathias; Jocelyn Booth; Kosalai Mohan; Elizabeth Stankevich; Hani M Babiker; Irene Brana; Marta Gil-Martin; Jade Homsi; Melissa L Johnson; Victor Moreno; Jiaxin Niu; Taofeek K Owonikoko; Kyriakos P Papadopoulos; George D Yancopoulos; Israel Lowy; Matthew G Fury
Journal: N Engl J Med Date: 2018-06-04 Impact factor: 91.245

2 in total

39 in total

1. mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).

Authors: Golnaz Kamalinia; Brian J Engel; Anupallavi Srinivasamani; Brian J Grindel; Justin N Ong; Michael A Curran; Terry T Takahashi; Steven W Millward; Richard W Roberts
Journal: ACS Chem Biol Date: 2020-04-30 Impact factor: 5.100

Review 2. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

Authors: Subashini Sharon Gnanendran; Lauren Maree Turner; James Austin Miller; Shelley Ji Eun Hwang; Andrew Charles Miller
Journal: Curr Treat Options Oncol Date: 2020-03-19

3. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.

Authors: G de Jong; L Bartels; M Kedde; E M E Verdegaal; M A Gillissen; S E Levie; M G Cercel; S E van Hal-van Veen; C Fatmawati; D van de Berg; E Yasuda; Y B Claassen; A Q Bakker; S H van der Burg; R Schotte; J Villaudy; H Spits; M D Hazenberg; P M van Helden; K Wagner
Journal: Cancer Immunol Immunother Date: 2020-11-23 Impact factor: 6.968

Cemiplimab: First Global Approval.

1. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.

2. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

1. mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).

Review 2. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

3. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.

Review 4. Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships.

5. In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action.

Review 6. Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.

Review 7. Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma.

8. Resistance to Immunotherapy: Mechanisms and Means for Overcoming.

Review 9. Scientifically based combination therapies with immuno-oncology checkpoint inhibitors.

Review 10. Polysaccharide-based nanomedicines for cancer immunotherapy: A review.